First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
==========================================================================================================================================================================

* Shengxiang Ren
* Xicheng Wang
* Bao-Hui Han
* Yueyin Pan
* Jun Zhao
* Yufeng Cheng
* Sheng Hu
* Tianshu Liu
* Yalun Li
* Ying Cheng
* Jifeng Feng
* Shanyong Yi
* Shanzhi Gu
* Shegan Gao
* Yongzhong Luo
* Ying Liu
* Caigang Liu
* Huijie Duan
* Shuni Wang
* Xinfeng Yang
* Jia Fan
* Caicun Zhou